AstraZeneca’s Vaxzevria (AZD1222) Delivers Strong Immune Responses in COV001 and COV002 Trials Against COVID-19
AstraZeneca’s Lokelma Receives Fast Track Designation for the Treatment of Chronic Haemodialysis with Hyperkalaemia
Shots:
- A sub-analysis from the Oxford’ P-I/II COV001 & P-II/III COV002 trials for Vaxzevria (as single or two doses) in patients aged 18 to 55yrs., demonstrated strong immune responses following 2nd dose interval @45wks. & following 3rd boosting dose. The Ab levels remain uplifted from baseline @1yr. following a single dose
- An extended interval b/w 1st & 2nd dose of Vaxzevria @45wks. resulted in 18 times increase in Ab response measured by 28 days after the 2nd dose.
- Additionally, third dose of Vaxzevria @6mos. resulted in 6 times increase in Abs levels & maintained T cell response and showed higher neutralizing activity against Alpha (B.1.1.7), Beta (B.1.351) & Delta (B.1.617.2) variants
Click here to read full press release/ article | Ref: AstraZeneca | Image: AstraZeneca